PRQR: AX-0811 entered the clinic, with five trial readouts and major AI-driven advances expected this yearQuartr·Sep 9 at 04:38 PMPRQR+1.61%
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026Unusual Whales·Sep 9 at 12:02 PMPRQR+1.61%
Commercial Expansions and Late-Stage Pipeline Milestones Drive 2026 Sector GrowthGlobal Report·Sep 8 at 11:33 AMRZLV+2.25%ARGX+1.13%
Inside the Broad Sector Reshuffle: Medtronic, Estée Lauder, and 8 Other Moves to WatchGlobal Report·Sep 8 at 09:19 AMHESAY-0.99%PRQR+1.61%
Gene Editing's 2026 Reality Check: Billion-Dollar Bets and the AI HorizonGlobal Report·Jul 22 at 09:17 AMVRTX+0.60%CRSP+9.80%
ProQR Therapeutics director Bart Filius buys $257,925 of common sharesPUBT·Jul 21 at 12:00 PMPRQR+1.61%
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above 50-Day Moving Average - Here's WhyMarket Beat·Jul 21 at 07:40 AMPRQR+1.61%
